Literature DB >> 1353708

A comparison of esmolol and labetalol for the treatment of perioperative hypertension in geriatric ambulatory surgical patients.

P P Singh1, I Dimich, I Sampson, N Sonnenklar.   

Abstract

This is an open randomized study comparing the efficacy and safety of i.v. esmolol and labetalol in the treatment of perioperative hypertension in ambulatory surgery. Twenty-two elderly patients undergoing cataract surgery under local anaesthesia were studied. The main inclusion criteria were development of systolic blood pressure greater than 200 mmHg or diastolic greater than 100 mmHg. Esmolol was given as a bolus 500 micrograms.kg-1 i.v. followed by a maintenance infusion (150-300 micrograms.kg-1.min-1). Labetalol was given as a bolus of 5 mg i.v. followed by 5 mg increments as needed up to a maximum of 1 mg.kg-1. Esmolol and labetalol both produced reductions in systolic and diastolic blood pressure (P less than 0.05) within ten minutes of administration which lasted for at least two hours. Reduction of blood pressure by esmolol was accompanied by a decrease in HR (P less than 0.05). Two patients developed extreme bradycardia (HR less than 50 beats.min-1) and esmolol had to be discontinued. Labetalol, in contrast, induced only a moderate decrease in HR. None of the patients treated with labetalol experienced any prolonged side effects such as orthostatic hypotension. In conclusion, esmolol may produce considerable bradycardia in elderly patients when hypertension is not accompanied by tachycardia. Labetalol was easier to administer in the ambulatory setting and one-tenth the cost of esmolol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353708     DOI: 10.1007/BF03008318

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  9 in total

1.  Alterations in the cardiovascular system that occur in advanced age.

Authors:  E G Lakatta
Journal:  Fed Proc       Date:  1979-02

2.  Reduced beta-adrenoceptor sensitivity in the elderly.

Authors:  R E Vestal; A J Wood; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

3.  Intravenous labetalol for treatment of postoperative hypertension.

Authors:  J B Leslie; R W Kalayjian; M A Sirgo; J R Plachetka; W D Watkins
Journal:  Anesthesiology       Date:  1987-09       Impact factor: 7.892

4.  The effect of age on the responses of human isolated arteries to noradrenaline.

Authors:  P J Scott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

5.  Intravenous labetalol in the management of severe hypertension and hypertensive emergencies.

Authors:  M D Cressman; D G Vidt; R W Gifford; W S Moore; D J Wilson
Journal:  Am Heart J       Date:  1984-05       Impact factor: 4.749

6.  Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies.

Authors:  D J Wilson; J D Wallin; N D Vlachakis; E D Freis; D G Vidt; E L Michelson; H G Langford; W Flamenbaum; M P Poland
Journal:  Am J Med       Date:  1983-10-17       Impact factor: 4.965

7.  Cardiovascular effects of esmolol in anesthetized humans.

Authors:  P G Menkhaus; J G Reves; I Kissin; J M Alvis; A V Govier; P N Samuelson; W A Lell; C E Henling; E Bradley
Journal:  Anesth Analg       Date:  1985-03       Impact factor: 5.108

8.  Pharmacology and pharmacokinetics of esmolol.

Authors:  R D Reynolds; R J Gorczynski; C Y Quon
Journal:  J Clin Pharmacol       Date:  1986-03       Impact factor: 3.126

9.  Esmolol and the adrenergic response to perioperative stimuli.

Authors:  V S Murthy; T F Hwang; B W Sandage; A R Laddu
Journal:  J Clin Pharmacol       Date:  1986-03       Impact factor: 3.126

  9 in total
  3 in total

Review 1.  Drugs for the perioperative control of hypertension: current issues and future directions.

Authors:  Robert Feneck
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

3.  Blood Loss and Visibility with Esmolol vs Labetalol in Endoscopic Sinus Surgery: A Randomized Clinical Trial.

Authors:  Philip F Lavere; Nikunj A Rana; Michael P Kinsky; J Sean Funston; Sharif S Mohamed; Mohamad R Chaaban
Journal:  Clin Med Insights Ear Nose Throat       Date:  2019-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.